Pericellular proteolysis in cancer

Genes and Development

Volumn 28, Issue 21, 2014, Pages 2331-2347

  Sevenich, Lisa ^a   Joyce, Johanna A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Invasion; Macrophages; Metastasis; Migration; Proteases; Tumor Microenvironment

Indexed keywords

PROTEINASE; ENZYME INHIBITOR; PEPTIDE HYDROLASE;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CELL TRANSFER; ENZYME REGULATION; EXOSOME; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PERICELLULAR PROTEOLYSIS; PROTEIN DEGRADATION; REVIEW; TUMOR INVASION; TUMOR MICROENVIRONMENT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT;

ENZYME ACTIVATION; ENZYME INHIBITORS; EXOSOMES; NEOPLASMS; PEPTIDE HYDROLASES; PROTEIN TRANSPORT; PROTEOLYSIS; TUMOR MICROENVIRONMENT;

EID: 84907570265     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.250647.114     Document Type: Review

References (214)

1. Affara NI, Andreu P, Coussens LM. 2009. Delineating protease functions during cancer development. Methods Mol Biol 539: 1–32.
2. Akkari L, Gocheva V, Kester JC, Hunter KE, Quick ML, Sevenich L, Wang H-W, Peters C, Tang LH, Klimstra D, et al. 2014. Distinct functions of macrophage-and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes Dev 28: 2134–2150.
3. Almeida PC, Nantes IL, Rizzi CC, Judice WA, Chagas JR, Juliano L, Nader HB, Tersariol IL. 1999. Cysteine proteinase activity regulation: a possible role of heparin and heparin-like glycosaminoglycans. J Biol Chem 274: 30433–30438.
4. Almeida PC, Nantes IL, Chagas JR, Rizzi CC, Faljoni-Alario A, Carmona E, Juliano L, Nader HB, Tersariol IL. 2001. Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation. J Biol Chem 276: 944–951.
5. Antalis TM, Bugge TH, Wu Q. 2011. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 99: 1–50.
6. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. 2006. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034–3043.
7. auf dem Keller U, Doucet A, Overall CM. 2007. Protease research in the era of systems biology. Biol Chem 388: 1159–1162.
8. Baker EA, Bergin FG, Leaper DJ. 2000. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 53: 307–312.
9. Baxter RC. 2014. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 14: 329–341.
10. Bellon G, Martiny L, Robinet A. 2004. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol 49: 203–220.
11. Bendrik C, Karlsson L, Dabrosin C. 2010. Increased endostatin generation and decreased angiogenesis via MMP-9 by tamoxifen in hormone dependent ovarian cancer. Cancer Lett 292: 32–40.
12. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737–744.
13. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U. 2001. PDGF-D is a specific, proteaseactivated ligand for the PDGFb-receptor. Nat Cell Biol 3: 512–516.
14. Bharadwaj A, Bydoun M, Holloway R, Waisman D. 2013. Annexin A2 heterotetramer: structure and function. Int J Mol Sci 14: 6259–6305.
15. Blasi F, Sidenius N. 2010. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584: 1923–1930.
16. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E. 2004. CD44 interaction with Na+–H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 279: 26991–27007.
17. Bracken CP, Li X, Wright JA, Lawrence D, Pillman KA, Salmanidis M, Anderson MA, Dredge BK, Gregory PA, Tsykin A, et al. 2014. Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion. EMBO J 33: 2040–2056.
18. Brauer R, Beck IM, Roderfeld M, Roeb E, Sedlacek R. 2011. Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen. BMC Biochem 12: 38.
19. Brisson L, Reshkin SJ, Gore J, Roger S. 2012. pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol 91: 847–860.
20. Brix K, Dunkhorst A, Mayer K, Jordans S. 2008. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 90: 194–207.
21. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin avb3. Cell 85: 683–693.
22. Brouxhon SM, Kyrkanides S, Teng X, Athar M, Ghazizadeh S, Simon M, O’Banion MK, Ma L. 2014. Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling. Oncogene 33: 225–235.
23. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. 2000. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578–583.
24. Buschman MD, Bromann PA, Cejudo-Martin P, Wen F, Pass I, Courtneidge SA. 2009. The novel adaptor protein Tks4 (SH3PXD2B) is required for functional podosome formation. Mol Biol Cell 20: 1302–1311.
25. Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, Yang Y, Wang L, Cao X, Wang J. 2012. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol 188: 5954–5961.
26. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, et al. 2012. Dependency of colorectal cancer on a TGF-b-driven program in stromal cells for metastasis initiation. Cancer Cell 22: 571–584.
27. Carmeliet P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389–395.
28. Cavallo-Medved D, Sloane BF. 2003. Cell-surface cathepsin B: understanding its functional significance. Curr Top Dev Biol 54: 313–341.
29. Cavallo-Medved D, Dosescu J, Linebaugh BE, Sameni M, Rudy D, Sloane BF. 2003. Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. Neoplasia 5: 507–519.
30. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. 2005. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 118: 1493–1503.
31. Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, Sloane BF. 2009. Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res 315: 1234–1246.
32. Chabottaux V, Ricaud S, Host L, Blacher S, Paye A, Thiry M, Garofalakis A, Pestourie C, Gombert K, Bruyere F, et al. 2009.Membrane-type 4matrixmetalloproteinase (MT4-MMP) induces lung metastasis by alteration of primary breast tumour vascular architecture. J Cell Mol Med 13: 4002–4013.
33. Chalaris A, Gewiese J, Paliga K, Fleig L, Schneede A, Krieger K, Rose-John S, Scheller J. 2010. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by l-secretase. Biochim Biophys Acta 1803: 234–245.
34. Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Furst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH, et al. 2013. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the ‘a disintegrin and metalloproteases’ 10 and 17. Int J Cancer 133: 1557–1566.
35. Collette J, Bocock JP, Ahn K, Chapman RL, Godbold G, Yeyeodu S, Erickson AH. 2004. Biosynthesis and alternate targeting of the lysosomal cysteine protease cathepsin L. Int Rev Cytol 241: 1–51.
36. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD. 1998. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161: 6845–6852.
37. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387–2392.
38. Crawford LJ, Irvine AE. 2013. Targeting the ubiquitin proteasome system in haematological malignancies. Blood Rev 27: 297–304.
39. Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari M, Yiotakis A, Dive V. 2005. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 87: 393–402.
40. Dalmay T, Edwards DR. 2006. MicroRNAs and the hallmarks of cancer. Oncogene 25: 6170–6175.
41. Davis GE, Bayless KJ, Davis MJ, Meininger GA. 2000. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol 156: 1489–1498.
42. Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, et al. 2009. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 15: 4058–4065.
43. De Meester I, Korom S, Van Damme J, Scharpe S. 1999. CD26, let it cut or cut it down. Immunol Today 20: 367–375.
44. Dennemarker J, Lohmuller T, Mayerle J, Tacke M, Lerch MM, Coussens LM, Peters C, Reinheckel T. 2010. Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene 29: 1611–1621.
45. Depner S, Lederle W, Gutschalk C, Linde N, Zajonz A, Mueller MM. 2014. Cell type specific interleukin-6 induced responses in tumor keratinocytes and stromal fibroblasts are essential for invasive growth. Int J Cancer 135: 551–562.
46. Drag M, Salvesen GS. 2010. Emerging principles in proteasebased drug discovery. Nat Rev Drug Discov 9: 690–701.
47. Duffy MJ. 1996. Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613–618.
48. Dyczynska E, Syta E, Sun D, Zolkiewska A. 2008. Breast cancerassociated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. Int J Cancer 122: 2634–2640.
49. Edwards DR, Handsley MM, Pennington CJ. 2008. The ADAM metalloproteinases. Mol Aspects Med 29: 258–289.
50. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, et al. 2004. Functional proteomic screens reveal an essential extracellular role for hsp90a in cancer cell invasiveness. Nat Cell Biol 6: 507–514.
51. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. 2000. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19: 1187–1194.
52. Feng S, Cen J, Huang Y, Shen H, Yao L, Wang Y, Chen Z. 2011. Matrix metalloproteinase-2 and-9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS ONE 6: e20599.
53. Fingleton B. 2007. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 13: 333–346.
54. Fiore E, Fusco C, Romero P, Stamenkovic I. 2002. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21: 5213–5223.
55. Fischer A. 1946. Mechanism of the proteolytic activity of malignant tissue cells. Nature 157: 442.
56. Fortelny N, Cox JH, Kappelhoff R, Starr AE, Lange PF, Pavlidis P, Overall CM. 2014. Network analyses reveal pervasive functional regulation between proteases in the human protease web. PLoS Biol 12: e1001869.
57. Friedrich R, Fuentes-Prior P, Ong E, Coombs G, Hunter M, Oehler R, Pierson D, Gonzalez R, Huber R, Bode W, et al. 2002. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J Biol Chem 277: 2160–2168.
58. Fukuda H, Mochizuki S, Abe H, Okano HJ, Hara-Miyauchi C, Okano H, Yamaguchi N, Nakayama M, D’Armiento J, Okada Y. 2011. Host-derived MMP-13 exhibits a protective role in lung metastasis ofmelanoma cells by local endostatin production. Br J Cancer 105: 1615–1624.
59. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. 2005. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 87: 361–368.
60. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM. 2008. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28: 5369–5380.
61. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, et al. 2008. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 453: 940–943.
62. Gerweck LE, Seetharaman K. 1996. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 56: 1194–1198.
63. Ghajar CM, George SC, Putnam AJ. 2008. Matrix metalloproteinase control of capillary morphogenesis. Crit Rev Eukaryot Gene Expr 18: 251–278.
64. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. 2006. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20: 543–556.
65. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA. 2010. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24: 241–255.
66. Godefroy E, Manches O, Dreno B, Hochman T, Rolnitzky L, Labarriere N, Guilloux Y, Goldberg J, Jotereau F, Bhardwaj N. 2011. Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12-and OX40L-dependent pathway. Cancer Cell 19: 333–346.
67. Gorelik L, Flavell RA. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factorb signaling in T cells. Nat Med 7: 1118–1122.
68. Gould CM, Courtneidge SA. 2014. Regulation of invadopodia by the tumor microenvironment. Cell Adhes Migr 8: 226–235.
69. Grabowska MM, Sandhu B, Day ML. 2012. EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal 24: 532–538.
70. Grass GD, Bratoeva M, Toole BP. 2012. Regulation of invadopodia formation and activity by CD147. J Cell Sci 125: 777–788.
71. Grass GD, Tolliver LB, Bratoeva M, Toole BP. 2013. CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness. J Biol Chem288: 26089–26104.
72. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. 2012. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38: 904–910.
73. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J. 2007. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765–770.
74. Hakulinen J, Sankkila L, Sugiyama N, Lehti K, Keski-Oja J. 2008. Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J Cell Biochem 105: 1211–1218.
75. Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W, Ferreira V, Fontijn RD, David G, Hommes DW, Lamers CB, et al. 2008. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 44: 1904–1913.
76. Hawinkels LJ, Paauwe M, Verspaget HW, Wiercinska E, van der Zon JM, van der Ploeg K, Koelink PJ, Lindeman JH, Mesker W, ten Dijke P, et al. 2014. Interaction with colon cancer cells hyperactivates TGF-b signaling in cancer-associated fibroblasts. Oncogene 33: 97–107.
77. Hemers E, Duval C, McCaig C, Handley M, Dockray GJ, Varro A. 2005. Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial–mesenchymal signaling. Cancer Res 65: 7363–7369.
78. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. 1998. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95: 365–377.
79. Hood JD, Cheresh DA. 2002. Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91–100.
80. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. 1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031–26037.
81. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, et al. 2006. Structure of human urokinase plasminogen activator in complex with its receptor. Science 311: 656–659.
82. Huguenin M, Muller EJ, Trachsel-Rosmann S, Oneda B, Ambort D, Sterchi EE, Lottaz D. 2008. The metalloprotease meprinb processes E-cadherin and weakens intercellular adhesion. PLoS ONE 3: e2153.
83. Hurst NJ Jr, Najy AJ, Ustach CV, Movilla L, Kim HR. 2012. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem J 441: 909–918.
84. Juncker-Jensen A, Deryugina EI, Rimann I, Zajac E, Kupriyanova TA, Engelholm LH, Quigley JP. 2013. Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination. Cancer Res 73: 4196–4211.
85. Kaminski A, Hahne JC, Haddouti E-M, Florin A, Wellmann A, Wernert N. 2006. Tumour–stroma interactions between metastatic prostate cancer cells and fibroblasts. Int J Mol Med 18: 941–950.
86. Karagiannis ED, Popel AS. 2006. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. J Theor Biol 238: 124–145.
87. Kenig S, Alonso MB, Mueller MM, Lah TT. 2010. Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett 289: 53–61.
88. Kessenbrock K, Plaks V, Werb Z. 2010. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52–67.
89. Kothari P, Pestana R, Mesraoua R, Elchaki R, Khan KM, Dannenberg AJ, Falcone DJ. 2014. IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages. J Immunol 192: 349–357.
90. Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Clement MV. 2009. Repression of NHE1 expression by PPARg activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer Res 69: 8636–8644.
91. Lechner AM, Assfalg-Machleidt I, Zahler S, Stoeckelhuber M, Machleidt W, Jochum M, Nagler DK. 2006. RGD-dependent binding of procathepsin X to integrin avb3 mediates celladhesive properties. J Biol Chem 281: 39588–39597.
92. Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, Angel P, Mueller MM. 2010. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 31: 1175–1184.
93. Lee MH, Dodds P, Verma V, Maskos K, Knauper V, Murphy G. 2003. Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-a converting enzyme. Biochem J 371: 369–376.
94. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. 2005. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169: 681–691.
95. Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, Hague MN, Ablack A, Carmine-Simmen K, McPherson VA et al. 2014. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep 8: 1558–1570.
96. Li L, Li H. 2013. Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors. Cancer Biol Ther 14: 796–805.
97. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, et al. 2000. PDGF-C is a new protease-activated ligand for the PDGF a-receptor. Nat Cell Biol 2: 302–309.
98. Li CM, Chen G, Dayton TL, Kim-Kiselak C, Hoersch S, Whittaker CA, Bronson RT, Beer DG, Winslow MM, Jacks T. 2013. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev 27: 1557–1567.
99. Lijnen HR, Ugwu F, Bini A, Collen D. 1998. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37: 4699–4702.
100. Lilja H, Ulmert D, Vickers AJ. 2008. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8: 268–278.
101. Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B, Li JD, Basbaum C. 1998. Tumor-derived EMMPRIN (extracel-lular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett 441: 88–92.
102. Lingwood D, Simons K. 2010. Lipid rafts as a membraneorganizing principle. Science 327: 46–50.
103. Liou GY, Doppler H, Necela B, Krishna M, Crawford HC, Raimondo M, Storz P. 2013. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kB and MMPs. J Cell Biol 202: 563–577.
104. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. 2000. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res 60: 6061–6067.
105. Liu Z, Xiong M, Gong J, Zhang Y, Bai N, Luo Y, Li L, Wei Y, Liu Y, Tan X, et al. 2014. Legumain protease-activated TATliposome cargo for targeting tumours and their microenvironment. Nat Commun 5: 4280.
106. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. 1997. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139: 1861–1872.
107. Lopez-Otin C, Bond JS. 2008. Proteases: multifunctional enzymes in life and disease. J Biol Chem 283: 30433–30437.
108. Lopez-Otin C, Hunter T. 2010. The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 10: 278–292.
109. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massague J, Kang Y. 2009. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 23: 1882–1894.
110. Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E et al. 2014. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov doi: 10.1158/2159-8290.CD-13-1010.
111. Lund IK, Illemann M, Thurison T, Christensen IJ, Hoyer-Hansen G. 2011. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets 12: 1744–1760.
112. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, et al. 2005. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7: 485–496.
113. Lynch CC, Vargo-Gogola T, Martin MD, Fingleton B, Crawford HC, Matrisian LM. 2007. Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor. Cancer Res 67: 6760–6767.
114. Ma DH, Yao JY, Kuo MT, See LC, Lin KY, Chen SC, Chen JK, Chao AS, Wang SF, Lin KK. 2007. Generation of endostatin by matrix metalloproteinase and cathepsin from human limbocorneal epithelial cells cultivated on amniotic membrane. Invest Ophthalmol Vis Sci 48: 644–651.
115. Mac Gabhann F, Popel AS. 2008. Systems biology of vascular endothelial growth factors. Microcirculation 15: 715–738.
116. Major TC, Liang L, Lu X, Rosebury W, Bocan TM. 2002. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 22: 1200–1207.
117. Makowski GS, Ramsby ML. 1998. Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. Inflammation 22: 287–305.
118. Mantovani A, Locati M. 2013. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 33: 1478–1483.
119. Marrero-Diaz R, Bravo-Cordero JJ, Megias D, Garcia MA, Bartolome RA, Teixido J, Montoya MC. 2009. Polarized MT1-MMP–CD44 interaction and CD44 cleavage during cell retraction reveal an essential role for MT1-MMP in CD44-mediated invasion. Cell Motil Cytoskeleton 66: 48–61.
120. Mason SD, Joyce JA. 2011. Proteolytic networks in cancer. Trends Cell Biol 21: 228–237.
121. Mathews JA, Gibb DR, Chen BH, Scherle P, Conrad DH. 2010. CD23 Sheddase A disintegrin and metalloproteinase 10 (ADAM10) is also required for CD23 sorting into B cellderived exosomes. J Biol Chem 285: 37531–37541.
122. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S, Takada T. 2010. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 184: 1543–1551.
123. McCready J, Sims JD, Chan D, Jay DG. 2010. Secretion of extracellular hsp90a via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 10: 294.
124. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. 2005. Genes that mediate breast cancer metastasis to lung. Nature 436: 518–524.
125. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. 2001. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61: 577–581.
126. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T, Ochiai A. 2004. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 64: 665–671.
127. Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y. 2004. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 315: 79–84.
128. Mohamed MM, Sloane BF. 2006. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6: 764–775.
129. Mohamed MM, Cavallo-Medved D, Rudy D, Anbalagan A, Moin K, Sloane BF. 2010. Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell Physiol Biochem 25: 315–324.
130. Monboisse JC, Oudart JB, Ramont L, Brassart-Pasco S, Maquart FX. 2014. Matrikines from basement membrane collagens: a new anti-cancer strategy. Biochim Biophys Acta 1840: 2589–2598.
131. Moser B, Wolf M, Walz A, Loetscher P. 2004. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25: 75–84.
132. Moses MA, O’Reilly MS. 2003. Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2. Methods Mol Med 74: 375–390.
133. Murphy G. 2008. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8: 929–941.
134. Murphy DA, Courtneidge SA. 2011. The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 12: 413–426.
135. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. 2012. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 11: M111.014647.
136. Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO. 2014a. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. Elife 3: e01308.
137. Naba A, Clauser KR, Whittaker CA, Carr SA, Tanabe KK, Hynes RO. 2014b. Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer 14: 518.
138. Nagase H, Visse R, Murphy G. 2006. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562–573.
139. Najy AJ, Day KC, Day ML. 2008. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 283: 18393–18401.
140. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. 2001. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114: 111–118.
141. Noskova V, Ahmadi S, Asander E, Casslen B. 2009. Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Gynecol Oncol 115: 121–126.
142. Notohamiprodjo S, Djafarzadeh R, Rieth N, Hofstetter M, Jaeckel C, Nelson PJ. 2012. Cell surface engineering of renal cell carcinoma with glycosylphosphatidylinositol-anchored TIMP-1 blocks TGF-b1 activation and reduces regulatory ID gene expression. Biol Chem 393: 1463–1470.
143. Ohashi K, Naruto M, Nakaki T, Sano E. 2003. Identification of interleukin-8 converting enzyme as cathepsin L. Biochim Biophys Acta 1649: 30–39.
144. Olson MW, Toth M, Gervasi DC, Sado Y, Ninomiya Y, Fridman R. 1998. High affinity binding of latent matrix metalloproteinase-9 to the a2(IV) chain of collagen IV. J Biol Chem 273: 10672–10681.
145. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA. 1997. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186: 1865–1872.
146. Overall CM, Lopez-Otin C. 2002. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657–672.
147. Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J, Harris JL, Ellis V. 2010. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J 426: 219–228.
148. Palermo C, Joyce JA. 2008. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 29: 22–28.
149. Papadimitropoulou A, Mamalaki A. 2013. The glycosylated IgII extracellular domain of EMMPRIN is implicated in the induction of MMP-2. Mol Cell Biochem 379: 107–113.
150. Parton RG, Simons K. 2007. The multiple faces of caveolae. Nat Rev Mol Cell Biol 8: 185–194.
151. Patterson BC, Sang QA. 1997. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem272: 28823–28825.
152. Peinado H, Lavotshkin S, Lyden D. 2011. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21: 139–146.
153. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, et al. 2012. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18: 883–891.
154. Peng KW, Vile R, Cosset FL, Russell S. 1999. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 6: 1552–1557.
155. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, et al. 1998. An essential role for ectodomain shedding in mammalian development. Science 282: 1281–1284.
156. Petrella BL, Vincenti MP. 2012. Interleukin-1b mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein b. Cancer Med 1: 17–27.
157. Piperi C, Papavassiliou AG. 2012. Molecular mechanisms regulating matrix metalloproteinases. Curr Top Med Chem 12: 1095–1112.
158. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. 1999. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9: 1441–1447.
159. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. 2005. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 92: 921–928.
160. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J. 1998. Amino-terminal truncation of chemokines by CD26/ dipeptidyl-peptidase IV: conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 273: 7222–7227.
161. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. 2003. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 4: 544–558.
162. Qi Y, Duhachek-Muggy S, Li H, Zolkiewska A. 2014. Phenotypic diversity of breast cancer-related mutations in metalloproteinase–disintegrin ADAM12. PLoS ONE 9: e92536.
163. Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat Med 19: 1423–1437.
164. Ra HJ, Harju-Baker S, Zhang F, Linhardt RJ, Wilson CL, Parks WC. 2009. Control of promatrilysin (MMP7) activation and substrate-specific activity by sulfated glycosaminoglycans. J Biol Chem 284: 27924–27932.
165. Rafn B, Nielsen CF, Andersen SH, Szyniarowski P, Corcelle-Termeau E, Valo E, Fehrenbacher N, Olsen CJ, Daugaard M, Egebjerg C, et al. 2012. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol Cell 45: 764–776.
166. Rakashanda S, Rana F, Rafiq S, Masood A, Amin S. 2012. Role of proteases in cancer: a review. Biotechnol Mol Biol Rev 7: 90–101.
167. Rawlings ND, Waller M, Barrett AJ, Bateman A. 2014. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 42: D503–D509.
168. Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA, del Cerro MH, Van den Steen PE, Opdenakker G, Terol MJ, Garcia-Pardo A. 2008. a4b1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112: 169–178.
169. Reis ST, Pontes-Junior J, Antunes AA, Dall’Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR, Nesrallah AJ, Piantino C, et al. 2012. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol 12: 14.
170. Rosenblum G, Van den Steen PE, Cohen SR, Bitler A, Brand DD, Opdenakker G, Sagi I. 2010. Direct visualization of protease action on collagen triple helical structure. PLoS ONE 5: e11043.
171. Rothberg JM, Bailey KM, Wojtkowiak JW, Ben-Nun Y, Bogyo M, Weber E, Moin K, Blum G, Mattingly RR, Gillies RJ, et al. 2013. Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia 15: 1125–1137.
172. Rozhin J, Sameni M, Ziegler G, Sloane BF. 1994. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54: 6517–6525.
173. Ruffell B, Affara NI, Cottone L, Junankar S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M, et al. 2013. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 27: 2086–2098.
174. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT. 2002. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16: 2684–2698.
175. Ruoslahti E. 1996. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12: 697–715.
176. Sameshima T, Nabeshima K, Toole BP, Yokogami K, Okada Y, Goya T, Koono M, Wakisaka S. 2000. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brainderived fibroblasts. Cancer Lett 157: 177–184.
177. Sarrazin S, Lamanna WC, Esko JD. 2011. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3: a004952.
178. Schulte M, Reiss K, Lettau M, Maretzky T, Ludwig A, Hartmann D, de Strooper B, Janssen O, Saftig P. 2007. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ 14: 1040–1049.
179. Seals DF, Courtneidge SA. 2003. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7–30.
180. Seals DF, Azucena EF Jr, Pass I, Tesfay L, Gordon R, Woodrow M, Resau JH, Courtneidge SA. 2005. The adaptor protein Tks5/ Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell 7: 155–165.
181. Seidah NG, Prat A. 2012. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11: 367–383.
182. Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ, et al. 2014. Analysis of tumour-and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol 16: 876–888.
183. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. 2001. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61: 237–242.
184. Shimoda M, Principe S, Jackson HW, Luga V, Fang H, Molyneux SD, Shao YW, Aiken A, Waterhouse PD, Karamboulas C, et al. 2014. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat Cell Biol 16: 889–901.
185. Shin M, Kadowaki T, Iwata J, Kawakubo T, Yamaguchi N, Takii R, Tsukuba T, Yamamoto K. 2007. Association of cathepsin E with tumor growth arrest through angiogenesis inhibition and enhanced immune responses. Biol Chem 388: 1173–1181.
186. Sieuwerts AM, Klijn JG, Henzen-Logmand SC, Bouwman I, Van Roozendaal KE, Peters HA, Setyono-Han B, Foekens JA. 1998. Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-b1 (TGF b1) compared with factor(s) released by human epithelial-carcinoma cells. Int J Cancer 76: 829–835.
187. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
188. Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, Ziegler G. 1994. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci 107: 373–384.
189. Strongin AY. 2010. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 1803: 133–141.
190. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. 2005. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-a and TGF-b. J Cell Sci 118: 2143–2153.
191. Sun J, Hemler ME. 2001. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61: 2276–2281.
192. Sun D, Wang X, Zhang H, Deng L, Zhang Y. 2011. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int 35: 569–574.
193. Tang L, Han X. 2013. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 67: 179–182.
194. Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A, Condorelli G, et al. 2008. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 15: 762–772.
195. Turk B. 2006. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785–799.
196. Ueki N, Lee S, Sampson NS, Hayman MJ. 2013. Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease. Nat Commun 4: 2735.
197. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, et al. 2014. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156: 1002–1016.
198. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G. 2003. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/ CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 270: 3739–3749.
199. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM. 2002. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 408: 155–161.
200. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen BS, Almholt K, Bogyo M, et al. 2006. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 66: 5242–5250.
201. Veillard F, Saidi A, Burden RE, Scott CJ, Gillet L, Lecaille F, Lalmanach G. 2011. Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin. J Biol Chem 286: 37158–37167.
202. Vempati P, Popel AS, Mac Gabhann F. 2011. Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst Biol 5: 59.
203. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R, Shi GP. 2006. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281: 6020–6029.
204. Wang YH, Dong YY, Wang WM, Xie XY, Wang ZM, Chen RX, Chen J, Gao DM, Cui JF, Ren ZG. 2013. Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-kB pathways induced by paracrine cytokines. J Exp Clin Cancer Res 32: 51.
205. Weidle UH, Tiefenthaler G, Georges G. 2014. Proteases as activators for cytotoxic prodrugs in antitumor therapy. Cancer Genomics Proteomics 11: 67–79.
206. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS, Friedl P. 2007. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 9: 893–904.
207. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC. 2001. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154: 1069–1079.
208. Yamaguchi H, Takeo Y, Yoshida S, Kouchi Z, Nakamura Y, Fukami K. 2009. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res 69: 8594–8602.
209. Yana I, Sagara H, Takaki S, Takatsu K, Nakamura K, Nakao K, Katsuki M, Taniguchi S, Aoki T, Sato H, et al. 2007. Crosstalk between neovessels and mural cells directs the sitespecific expression of MT1-MMP to endothelial tip cells. J Cell Sci 120: 1607–1614.
210. Yang X, Wang D, Dong W, Song Z, Dou K. 2010. Inhibition of Na+/H+ exchanger 1 by 5-(N-ethyl-N-isopropyl) amiloride reduces hypoxia-induced hepatocellular carcinoma invasion and motility. Cancer Lett 295: 198–204.
211. Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Holtta E. 2012. TGF-b signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am J Pathol 181: 2202–2216.
212. Yong HY, Kim IY, Kim JS, Moon A. 2010. ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling. Int J Oncol 36: 501–507.
213. Yu Q, Stamenkovic I. 1999. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13: 35–48.
214. Yu Q, Stamenkovic I. 2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis. Genes Dev 14: 163–176.